GlassScriptPhysician profile
Eduardo Ignacio Canto
NPI 1366425506
$17,195.71
in general payments reported to CMS, 2019-2025
23 companies · $3,766 in 2025
The $3,766 reported for 2025 was more than what 89% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,785 · 2020: $2,081 · 2021: $6,686 · 2022: $601 · 2023: $1,680 · 2024: $596 · 2025: $3,766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Food and Beverage: $2,173 · Travel and Lodging: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Food and Beverage | $2,172.54 |
| Travel and Lodging | $869.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $7,826.53 | 2019-2025 | Keytruda |
| Intuitive Surgical, INC. | $4,036.41 | 2021 | |
| Boston Scientific Corporation | $1,180.10 | 2019-2025 | Ams 700 Cxr Rte Kit, General - Kidney Stone Disease, Lumenis Pulse 120h |
| Procept Biorobotics Corporation | $1,140.68 | 2025 | |
| Neotract INC. | $471.66 | 2019 | |
| Janssen Pharmaceuticals, INC | $464.10 | 2024-2025 | Erleada, Rybrevant, Talvey |
| Travere Therapeutics, INC. | $236.40 | 2019 | |
| Verity Pharmaceuticals INC. | $234.62 | 2025 | Tlando |
| E.R. Squibb & Sons, L.L.C. | $225.00 | 2024-2025 | Opdivo |
| Olympus Latin America, INC. | $198.62 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $187.73 | 2024-2025 | Adstiladrin |
| Astellas Pharma US INC | $144.47 | 2019-2022 | |
| Abbvie INC. | $125.00 | 2025 | |
| Urogen Pharma, INC. | $114.14 | 2022 | |
| Pfizer INC. | $100.25 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $100.00 | 2019 | |
| Momentis Surgical INC. | $73.00 | 2022 | |
| Profound Medical Corp. | $66.86 | 2025 | Tulsa-Pro |
| Tolmar, INC. | $66.20 | 2025 | Rubraca, Jatenzo, Eligard |
| Tolmar Pharmaceuticals, INC. | $64.41 | 2019 | |
| Janssen Biotech, INC. | $61.00 | 2019 | |
| Stryker Corporation | $41.46 | 2023 | Spy-Phi System |
| Pharmaand Gmbh | $37.07 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Canto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.